Phase IIT Trial of SNA014
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSmartNuclide Biopharma
About this trial
68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for gastric or gastroesophageal junction
Eligibility criteria
Qualifiers
Age range of 18 to 75 years old (including boundary values);
Individuals with behavioral capacity who voluntarily participate in this clinical study and sign an informed consent form (ICF);
Diagnosed G/GEJ adenocarcinoma and pancreatic cancer;
Gastroscopy/CT/MRI/PET-CT examination results within the past month (if any);
Disqualifiers
Uncontrolled severe infections or individuals with other serious illnesses;
Those with an expected survival period of less than or equal to three months;
Pregnant or lactating patients, as well as reproductive age patients who refuse to take appropriate contraceptive measures during this trial;
investigators determine that patients who are not suitable to participate in this study;
Trial design
Treatments tested in this trial
- [68Ga]Ga-NODAGA-SNA014
Treatment groups
28 Participants
are divided into 1 treatment groupLocations
1The First Affiliated Hospital of Soochow University215000, JiangsuProvince, China
Sponsors and collaborators
SmartNuclide Biopharma
Lead sponsor
Source ClinicalTrials.gov